stoxline Quote Chart Rank Option Currency Glossary
Nuvalent, Inc. (NUVL)
79.25  0.85 (1.08%)    06-21 16:00
Open: 78.65
High: 79.66
Volume: 657,642
Pre. Close: 78.4
Low: 77.715
Market Cap: 5,116(M)
Technical analysis
2024-06-21 4:54:15 PM
Short term     
Mid term     
Targets 6-month :  97.35 1-year :  113.7
Resists First :  83.34 Second :  97.35
Pivot price 76.53
Supports First :  71.55 Second :  64.26
MAs MA(5) :  78.14 MA(20) :  74.11
MA(100) :  75.19 MA(250) :  63.39
MACD MACD :  2.5 Signal :  2.2
%K %D K(14,3) :  75 D(3) :  72.2
RSI RSI(14): 62.5
52-week High :  89.38 Low :  38.77
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ NUVL ] has closed below upper band by 35.1%. Bollinger Bands are 54.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 79.78 - 80.1 80.1 - 80.43
Low: 76.93 - 77.26 77.26 - 77.6
Close: 78.7 - 79.28 79.28 - 79.88
Company Description

Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Headline News

Sat, 22 Jun 2024
Wellington Management Group LLP Sells 542,965 Shares of Nuvalent, Inc. (NASDAQ:NUVL) - MarketBeat

Sat, 22 Jun 2024
Wellington Management Group LLP Sells 542965 Shares of Nuvalent, Inc. (NASDAQ:NUVL) - Defense World

Sat, 22 Jun 2024
Recent Price Trend in Nuvalent, Inc. (NUVL) is Your Friend, Here's Why - Yahoo Sport Australia

Tue, 18 Jun 2024
Nuvalent to Participate in the 2022 Canaccord Genuity Horizons in Oncology Virtual Conference - Quantisnow

Tue, 18 Jun 2024
Insider Selling: Nuvalent, Inc. (NASDAQ:NUVL) Director Sells 5,000 Shares of Stock - MarketBeat

Tue, 04 Jun 2024
Nuvalent Rings the Opening Bell - Nasdaq

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 59 (M)
Shares Float 33 (M)
Held by Insiders 3 (%)
Held by Institutions 108.9 (%)
Shares Short 6,770 (K)
Shares Short P.Month 6,850 (K)
Stock Financials
EPS -2.43
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 10.47
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -18.4 %
Return on Equity (ttm) -26.1 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -111 (M)
Levered Free Cash Flow -59 (M)
Stock Valuations
PE Ratio -32.75
PEG Ratio 0
Price to Book value 7.56
Price to Sales 0
Price to Cash Flow -42.06
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android